Catalyst Financial Partners LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Catalyst Financial Partners LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 25.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,757 shares of the biopharmaceutical company’s stock after selling 4,413 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Pfizer were worth $367,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in PFE. E Fund Management Co. Ltd. raised its holdings in shares of Pfizer by 22.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 13,922 shares of the biopharmaceutical company’s stock worth $401,000 after buying an additional 2,514 shares during the last quarter. National Pension Service raised its stake in Pfizer by 2.1% in the 4th quarter. National Pension Service now owns 9,306,192 shares of the biopharmaceutical company’s stock worth $267,925,000 after acquiring an additional 192,179 shares during the last quarter. Blume Capital Management Inc. raised its stake in Pfizer by 87.7% in the 4th quarter. Blume Capital Management Inc. now owns 49,225 shares of the biopharmaceutical company’s stock worth $1,417,000 after acquiring an additional 23,000 shares during the last quarter. Bogart Wealth LLC lifted its position in Pfizer by 1.7% during the 4th quarter. Bogart Wealth LLC now owns 268,539 shares of the biopharmaceutical company’s stock worth $7,731,000 after acquiring an additional 4,543 shares during the period. Finally, Gryphon Financial Partners LLC grew its stake in Pfizer by 43.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 8,194 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PFE. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $36.00.

Pfizer Trading Up 1.8 %

Shares of PFE stock traded up $0.50 on Wednesday, hitting $28.28. 39,037,887 shares of the stock traded hands, compared to its average volume of 43,541,762. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The firm’s 50-day moving average price is $26.92 and its two-hundred day moving average price is $28.12. The stock has a market capitalization of $160.11 billion, a PE ratio of -471.17, a PEG ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.94%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.